Alterity Therapeutics Ltd. · ASX:ATH
Alterity Therapeutics — Prana Biotechnology — Corporate Update (January 2014)
18 slides from Alterity Therapeutics's corporate update, Jan 22, 2014
Slide 1: Company Update January 21-23, 2014
Company Update January 21 - 23, 2014
Slide 2: Safe Harbour
This presentation may contain some statements that may be considered “ Forward - Looking Statements ” , within the meaning of the US Securities Laws . Thus, any forward - looking statement relating to financial projections or other statements relating to the Company ’ s plans, objectives, expectatio
Slide 3: Public Market Overview
Public Market Overview NASDAQ: PRAN; ASX: PBT (as of 20th January 2014) PBT – AU shares ($ in AUD) Prana – US ADRs ($ in USD) Share Price: $0.83 $7.10 52 - Week Range AUD $0.20 – $0.84 $2.06 - $7.87 Shares on Issue 416.02 million PBT ordinary shares 41.602 million PRAN ADR equivalent PRAN ADR = 10 P
Slide 4: MPAC (Metal-Protein Attenuating Compounds) Technology
MPAC (Metal - Protein Attenuating Compounds) Technology • Age - related neurological conditions involve pathological interactions between selected metals and target proteins. • Metal - Protein Attenuating Compounds (MPACs) inhibit Alzheimer's - like changes in the brain by preventing a build up of b
Slide 5: Prana Asset Pipeline
Prana Asset Pipeline Phase II trial reporting in early 2014 Phase II trial reporting in March 2014 Product Indication Screening Preclinical toxicology Phase I Clinical trial Phase II Clinical trial Catalyst 2014 PBT2 PBT2 PBT434 PBT519 MPAC Library Huntington’s Disease Alzheimer’s Disease Parkinson’
Slide 6: How Does PBT2 work?
How Does PBT2 work? • Preclinical studies have shown that PBT2 potently interferes with the underlying toxic mechanisms of Alzheimer’s Disease & Huntington Disease. (i) Anti Abeta (AD) & mHtt (HD) effects : x Reduces Abeta aggregation x Promotes dissolution x Prevents toxicity x Promotes Abeta degra
Slide 7: PBT2 and Huntington's Disease
PBT2 and Huntington’s Disease • Huntington's Disease is a neurodegenerative disease caused by a mutated gene ( Htt ). • Death of specific brain cells causes gradual loss of cognitive (thinking), physical and emotional function. • Most commonly observed symptom is jerky involuntary movements of the a
Slide 8: Phase 2 Huntington's Disease Trial
Phase Population Treatment Status & Key Points II Early to Mid Stage Huntington's Disease in males/females. Number of participants: 109 PBT2 - 203 3 arm study: 100mg and 250 mg PBT2 versus placebo once daily for 26 weeks. Status: Completed. Results under analysis. Results due early 2014. Primary Obj
Slide 9: PBT2 and Alzheimer's Disease
PBT2 and Alzheimer’s Disease • Brain requires zinc and copper for healthy synaptic function and cognition. • In AD these metals become sequestered by amyloid deposits; hence not available. • PBT2 liberates these metals and restores them to usable pool in neurons. • In liberating the metals, PBT2 pre
Slide 10: Targeting Executive Function and Memory
Targeting Executive Function and Memory 8
Slide 11: Targeting Executive Function and Memory
Targeting Executive Function and Memory 9
Slide 12: Targeting Executive Function and Memory
Targeting Executive Function and Memory 10
Slide 13: Alzheimer's Disease Market
11 Alzheimer’s Disease Market • Six drugs approved, primarily for memory symptoms (Exelon, Aricept, Memary, Rivastach, Razadyne, Ebixa ). • $5.3 Billion in drug sales in 2012*. • No approved drug for disease modification. • Global market for AD ~US$10 billion # • Multiple phase 3 trial failures/chal
Slide 14: Phase 2a Trial Results
-0.1 -0.05 0 0.05 0.1 0.15 0.2 0.25 0.3 0.35 placebo n=28 250mg n=27 50mg n=19 p = 0.042 Phase 2a Trial Results* n = 74 • 78 mild AD patients; placebo (29), 50mg PBT2 qd (20), 250mg PBT2 qd (29): • ADAS - cog 10 - 25, MMSE 20 - 26; • 74 patients completed study; • 12 weeks of treatment; and • Double
Slide 15: Phase 2 Alzheimer's Disease Trial
Phase Population Treatment Status & Key Points II Prodromal or Mild Alzheimer's Disease in males/females over 55 years. Number of participants: 42 PBT2 - 204 2 arm study: 250mg PBT2 versus placebo once daily for 52 weeks Status : Complete. Results under analysis. 95% patient retention. Data safety m
Slide 16: IMAGINE extension trial
12 month IMAGINE extension trial Significant opportunity to collect a further 12 months data. 14 Phase Population Treatment Status & Key Points II Prodromal or Mild Alzheimer's Disease in males/females over 55 years. Number of participants: 33 PBT2 - 204 Open Label - 250mg PBT2 daily for further 52
Slide 17: Key Opinion Leaders
Targeting Metals in Alzheimer’s and Other Neurodegenerative Disease symposium hosted by New York Academy of Sciences in January 2013. Significant body of evidence supporting PBT - 2. Visit: http://www.nyas.org/Publications/Ebriefings/ Detail.aspx?cid=1fc1b1f4 - 1c78 - 46ba - 85a1 - 0763632fa129 Key
Slide 18: Thank you
16 Thank you Mr Geoffrey Kempler President and CEO Prana Biotechnology gkempler@pranabio.com SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PRANA BIOT
Prana Biotechnology — Corporate Update (January 2014) on 6ix